Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03236311
Other study ID # ACT14656
Secondary ID 2016-000629-38U1
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 12, 2017
Est. completion date July 23, 2018

Study information

Verified date March 2022
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically successful percutaneous coronary intervention (PCI). Secondary Objectives: - To assess the effects of SAR407899 on quality of life using Seattle Angina Questionnaire physical limitation scale (SAQ-PL) in participants with MVA and/or persistent stable angina despite angiographically successful PCI. - To assess the safety of SAR407899 in participants with MVA and/or persistent stable angina despite angiographically successful PCI with a focus on identified risks such as hypotension and orthostatic hypotension. - To assess SAR407899 plasma concentrations in MVA participants and/or persistent stable angina despite angiographically successful PCI.


Description:

The total duration of study per participant was: - up to 9 weeks for participants with previous coronary artery angiography or coronary computed tomography angiography (CCTA) within 24 months prior to screening with up to 4 weeks screening period, 3 weeks titration phase, 1 week maintenance period, and 1 week follow-up after the last investigational medicinal product administration. or - up to 11 weeks for participants with previous coronary artery angiography or CCTA between 24 months and 5 years prior to screening who need CCTA during screening period with up to 6 weeks screening period, 3 weeks titration phase, 1 week maintenance period, and 1 week follow-up after the last investigational medicinal product administration.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date July 23, 2018
Est. primary completion date July 23, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Male or female participants not at childbearing potential >=18 year-old or legal age of majority. - Female participant if she has undergone sterilization at least 3 months earlier or was post-menopausal. - Post-menopausal status was defined by having no menses for 12 months without an alternative medical cause. - In females not treated with hormonal replacement therapy (HRT), menopausal status was confirmed by a high follicle stimulating hormone (FSH) level greater than 40 international units per litre (IU/L). - In females on HRT and whose menopausal status was in doubt (i.e. in women aged less than 45 years), a highly effective contraception methods was required. Contraception was used during the whole study and for at least seven days corresponding to time needed to eliminate study treatment. - Symptomatic stable angina pectoris (typical or atypical symptoms with an average of at least bi-weekly episodes over the past month). - Participants with non-obstructive (<50% stenosis) coronary arteries or intermediate stenosis (between 50 and 70%) should have fractional flow reserve (FFR) >0.80 or instantaneous wave-free ratio (iFR) >0.89 on angiogram, documented within the previous 24 months*. In participants with stenting, a minimum diameter stenosis of <10% is required. or Coronary computed tomography angiography (CCTA) with finding of non-obstructive coronary arteries within the past 24 months* in participants without previous percutaneous coronary intervention (PCI). *Note: in cases of clinically suspected progression of atherosclerosis as per the Investigator, a more contemporary (i.e., 6 months) evidence should be provided. or CCTA performed during screening period, with finding of non-obstructive coronary arteries, in participants diagnosed with microvascular angina (MVA) and stable angina without previous PCI who did not have a coronary angiogram or CCTA in the previous 24 months but between 24 months to 5 years. - Baseline global coronary flow reserve (CFR) (measured during the study) assessed by 13N-ammonia or 82Rubidium positron emission tomography (PET) scan <2.0. Exclusion criteria: - Any use of nitrates (except short-acting nitrates) and/or dipyridamole and/or phosphodiesterase type 5 (PDE 5) inhibitors within one week prior to baseline PET scan or anticipated to be used during the study. - Esophageal dysmotility or esophagitis. - Participants with acute coronary syndrome (ACS) (myocardial infarction [MI] and/or unstable angina) in previous 3 months. - Unsuccessful or incomplete coronary revascularization with residual obstructive stenosis or coronary artery disease (CAD) progression in native vessels as documented on invasive coronary angiography (>=50% stenosis) within 24 months of enrollment. - Percutaneous coronary intervention performed at the time of an ACS (MI or unstable angina) in the previous 12 months. - Recent PCI within the past 3 months. - Participants with history of coronary artery bypass grafting (CABG). - Recent (<=3 months) major surgery (i.e. valvular surgery, surgery for congenital heart disease), stroke, transient ischemic attack [TIA], sustained ventricular arrhythmia, clinically significant structural heart disease (moderate-severe valvular disease, hypertrophic cardiomyopathy, congenital heart disease, pulmonary hypertension). - Regional local flow abnormal perfusion defects at baseline PET scan*. *Note: if contemporary evidence with invasive coronary angiography or CCTA demonstrates non-obstructive coronary arteries or if the regional local flow abnormal perfusion defect on PET scan is consistent with previous studies then participant qualifies for the study. - Participants with cardiac conduction abnormalities (second or third degree atrioventricular [AV] block, sick sinus syndrome, symptomatic bradycardia, sinus node disease) except in participants fitted with a functioning pacemaker. - History or known carotid stenosis: - Carotid stenosis (>50%) or - History of carotid stenosis in participants with previous symptoms. - Contraindication or known hypersensitivity to adenosine or regadenoson. - Contraindication to aminophylline. - Contraindication to vasodilator stress PET scan and/or CCTA if CCTA needed during screening. - Inability to discontinue treatment with methylxanthines treatment within 24 hours prior to PET scan. - Participant unable to read, understand and fill a questionnaire without any help (eg, partially visually impaired or blind). - Systolic blood pressure (SBP) <110 millimeter of mercury (mmHg) at baseline. - Presence at baseline of symptomatic orthostatic hypotension (SBP decrease of 20 mmHg or more at Minute 3 or Minute 5 between seated and standing position), or asymptomatic orthostatic hypotension with a decrease in SBP equal or greater than 30 mmHg at Minute 3 or Minute 5 when changing from the seated to the standing position. - Renal impairment with estimated glomerular filtration rate (eGFR) <50 milliliter/minute/1.73 square meter (mL/min/1.73 m^2) at screening and baseline. - Drug-induced liver injury related criteria: - Underlying hepatobiliary disease. - Alanine Aminotransferase (ALT) >3 times the upper limit of normal (ULN). The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SAR407899
Pharmaceutical form: Capsule Route of administration: Oral
Placebo
Pharmaceutical form: Capsule Route of administration: Oral
Adenosine
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Regadenoson
Pharmaceutical form: Solution for injection Route of administration: Intravenous
13N-ammonia
Pharmaceutical form: Solution for injection Route of administration: Intravenous
82Rubidium
Pharmaceutical form: Solution for injection Route of administration: Intravenous

Locations

Country Name City State
Denmark Investigational Site Number 2080001 København Nv
Korea, Republic of Investigational Site Number 4100002 Seoul
Netherlands Investigational Site Number 5280001 Nijmegen
Sweden Investigational Site Number 7520001 Lund
United States Investigational Site Number 8400008 Baltimore Maryland
United States Investigational Site Number 8400006 Boston Massachusetts
United States Investigational Site Number 8400001 Jacksonville Florida
United States Investigational Site Number 8400003 Los Angeles California
United States Investigational Site Number 8400010 Philadelphia Pennsylvania
United States Investigational Site Number 8400013 Wellington Florida

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Denmark,  Korea, Republic of,  Netherlands,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4 Absolute change from baseline to Week 4 in uncorrected global CFR, as assessed by the central core laboratory. The global CFR is the ratio of absolute myocardial blood flow (MBF) at stress over that at rest. The MBF was assessed by 13N-ammonia or 82Rubidium positron emission tomography (PET) scan. Baseline, Week 4
Secondary Change From Baseline in Angina-induced Physical Limitation Assessed Using Seattle Angina Questionnaire Physical Limitation Scale (SAQ-PL) at Week 4 The SAQ-PL measures how common daily activities representing low, medium, and high exertional requirements were limited by angina (9 items). It was scored by assigning each response an ordinal value, beginning with 1 for the response that implied the 'lowest level of functioning' to 5 for 'not at all limited', and summing across the 9 items. The score of 9 items was then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. The range of scores was 0 to 100, with higher scores indicates better functioning. A change of 10 points was considered to be clinically important. Baseline, Week 4
Secondary Pharmacokinetic Parameter: SAR407899 Plasma Concentration Day 1, 8, 15, 22, and Day 29
See also
  Status Clinical Trial Phase
Withdrawn NCT04069234 - Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention. Phase 3
Recruiting NCT04560829 - Additive Value of Physiology Coronary in Clinical Practice
Recruiting NCT06080919 - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI). N/A
Terminated NCT04614467 - A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction Phase 2
Recruiting NCT04541797 - Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) N/A
Recruiting NCT04598308 - EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial
Active, not recruiting NCT05197361 - Microvascular Coronary Resistance and Absolute Coronary FLOW in Patients With Percutaneous Intervention of a Chronic Total Occlusion
Recruiting NCT04827498 - Myocardial Ischemia Without Obstructive Coronary Stenoses
Suspended NCT05756088 - Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Recruiting NCT06118450 - Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients
Recruiting NCT03217227 - Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR
Completed NCT03462017 - Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus Phase 1
Not yet recruiting NCT06269874 - Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment N/A
Not yet recruiting NCT06217120 - Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction Phase 2/Phase 3
Recruiting NCT06316661 - CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF
Recruiting NCT04131075 - The Cerebral-Coronary Connection (C3) Study
Completed NCT04485234 - Inclusive Invasive Physiological Assessment in Angina Syndromes Registry
Completed NCT05471739 - Simultaneous Assessment of Coronary Microvascular Dysfunction and Ischemia With Non-obstructed Coronary Arteries With Intracoronary Electrocardiogram and Intracoronary Doppler
Completed NCT05406297 - Impact of TMAO Serum Levels on Hyperemic IMR in STEMI Patients
Not yet recruiting NCT06069401 - The MASTER-PACT Study